Search clinical trials for: interferon-alfa-2b and ribavirin

Total 4185 results

University Health Network, Toronto
Hoffmann-La Roche

Terminated

Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication

HIV Infections | Chronic Hepatitis C

Canada
Services Institute of Medical Sciences, Pakistan
Getz Pharma

Completed

The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients (HEP-C-FM)

Hepatitis C, Chronic | DIABETES MELLITUS Type 2

Pakistan
Chugai Pharmaceutical

Completed

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)

Liver Cirrhosis | Chronic Hepatitis C

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Hepatitis C, Chronic

Japan
Hoffmann-La Roche

Completed

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

China
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

Hepatitis C
Transgene

Completed

Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients (HCVac)

Chronic Hepatitis C Infection

Germany
National Taiwan University Hospital
National Science Council, Taiwan

Completed

Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C

Hepatitis C

Taiwan
Merck Sharp & Dohme LLC

Terminated

Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

Hepatitis C, Chronic
Third Affiliated Hospital, Sun Yat-Sen University
Peking University; Huazhong University of Science and Technology; First People... and other collaborators

Unknown

The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg

Chronic Hepatitis B

China
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Hepatitis C, Chronic
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Chronic Hepatitis C

France, United States, Puerto Rico
Vertex Pharmaceuticals Incorporated
Tibotec, Inc

Completed

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Hepatitis C

United States, France, United Kingdom, Germany, Canada, Netherlands, Austria, Puerto Rico
Pusan National University Yangsan Hospital
Pusan National University Hospital; Inje University; Severance Hospital; Soon Chun... and other collaborators

Unknown

PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

Chronic Hepatitis C

Korea, Republic of
Dermatologic Cooperative Oncology Group

Unknown

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Therapy | Adjuvant | Stage III Malignant Melanoma | Interferon Alpha

Germany
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Hepatitis C

United States, Canada, Germany, Puerto Rico, Spain
Beijing Ditan Hospital

Unknown

Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C

Chronic Hepatitis C

China
Foundation for Liver Research

Completed

Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB (PEGON)

Chronic Hepatitis B

Netherlands, China
Merck Sharp & Dohme LLC

Terminated

A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

Malignant Melanoma
French National Agency for Research on AIDS and...
Hoffmann-La Roche

Completed

Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients

HIV Infections | Chronic Hepatitis C

France
Cairo University

Unknown

Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c

Chronic Hepatitis c

Egypt
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

HIV Infections

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Refractory Melanoma | HLA-A2 Positive Cells Present

United States
PharmaEssentia Japan K.K.
PharmaEssentia

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

Australia
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3

Hepatitis C, Chronic

Austria
Hoffmann-La Roche

Completed

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Cancers

United States, Netherlands
The University of Hong Kong

Completed

Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC

Hepatocellular Carcinoma
Xiamen Amoytop Biotech Co., Ltd.
Peking University People's Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PEGIFN)

Chronic Hepatitis C

China
Pacific Health Foundation
Hoffmann-La Roche

Completed

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

Chronic Hepatitis C | Treatment | Asian Americans | Novel Genotypes

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Unspecified Childhood Solid Tumor, Protocol Specific | Neoplasm of Uncertain Malignant Potential

United States
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Hepatitis C Virus Genotype 4 Infection

France
Merck Sharp & Dohme LLC

Completed

PegIntron Injection Surveillance Plan (Study P04123)

Hepatitis C, Chronic
Case Comprehensive Cancer Center

Completed

Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery

Renal Cell Cancer | Stage IV Renal Cell Cancer

United States
Merck Sharp & Dohme LLC

Withdrawn

A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

Hepatitis C
Fang Wang

Recruiting

A Study on Antiviral Treatment of Chronic Hepatitis B in Children

Chronic HBV Infection

China
Lee's Pharmaceutical Limited

Unknown

Yallaferon in Chinese Population

HPV Infection

China
Intarcia Therapeutics

Completed

Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C

Hepatitis C

Russian Federation
Hoffmann-La Roche

Completed

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Renal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant Melanoma

Canada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
Huashan Hospital

Unknown

Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy

Chronic Hepatitis B

China
Novartis Pharmaceuticals
Human Genome Sciences Inc.

Terminated

Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

Chronic Hepatitis B

Taiwan, Poland, China, Hong Kong, Thailand
Rottapharm

Withdrawn

Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C (HEPASIL)

Hepatitis C, Chronic

Egypt
National Institute of Diabetes and Digestive and...

Completed

Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease

Chronic Hepatitis C

United States
PV-Nord

Completed

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

Polycythemia Vera

France
Chinese University of Hong Kong
Hoffmann-La Roche

Completed

Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment

Chronic Hepatitis B

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Mucosal Melanoma

China
Third Affiliated Hospital, Sun Yat-Sen University
Peking University; Huazhong University of Science and Technology; First People... and other collaborators

Unknown

HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients

Chronic Hepatitis B

China
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
José Antonio Carrion
Instituto de Salud Carlos III

Completed

HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients

Chronic Hepatitis B (HBeAg-negative)
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Hepatitis B

China
Merck Sharp & Dohme LLC

Withdrawn

A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)

Hepatitis B

3

Subscribe